Sermorelin vs CJC-1295/Ipamorelin vs Tesamorelin
All three act on the growth-hormone axis but in different ways. Sermorelin is a short GHRH analog. CJC-1295 with ipamorelin pairs a longer-acting GHRH analog with a selective GH secretagogue. Tesamorelin is a stabilized GHRH analog originally approved for a specific HIV-related indication. Use is determined by the prescribing clinician.
What's being compared
Short GHRH analog used historically in compounded protocols.
Longer-acting GHRH analog paired with a selective GH secretagogue.
Stabilized GHRH analog with an FDA-approved finished product for a specific indication.
Side-by-side comparison
| Attribute | Sermorelin | CJC-1295 / Ipamorelin | Tesamorelin |
|---|---|---|---|
| Class | GHRH analog (short) | GHRH analog (CJC-1295) plus GH secretagogue (ipamorelin) | Stabilized GHRH analog |
| Mechanism on the GH axis | Stimulates pituitary GH release through the GHRH receptor. | CJC-1295 extends GHRH-receptor signaling; ipamorelin selectively triggers GH release through the ghrelin/GHS-R pathway. | Stabilized analog that prolongs GHRH-receptor signaling versus native GHRH. |
| Common indications | Historically used in compounded GH-axis protocols; the prior FDA-approved finished product carried a pediatric growth indication and is no longer marketed. | Used as a clinician-directed compounded GH-axis protocol; no FDA-approved indications for the combined preparation. | FDA-approved finished product carries an indication for HIV-associated lipodystrophy in adults; clinicians decide patient fit. |
| Reported duration of action | Short (minutes range, per published data). | Hours-scale CJC-1295 activity combined with short ipamorelin pulses. | Longer than native GHRH; supports daily dosing schedules. |
| Typical dosing schedule | Daily subcutaneous in historical compounded protocols. | Daily or near-daily subcutaneous in clinician-directed protocols. | Daily subcutaneous in the FDA-approved labeling and in compounded protocols. |
| Route | Subcutaneous injection | Subcutaneous injection | Subcutaneous injection |
| Regulatory status | Compounded availability through 503A/503B pharmacies; the prior FDA-approved finished product was discontinued. | Compounded availability through 503A/503B pharmacies; not FDA-approved as a finished combined product. | FDA-approved finished product exists for a specific HIV-related indication; compounded forms also exist. |
| Evidence base | Long-standing pre-2010 clinical literature on the discontinued finished product; modern compounded use draws on that evidence base. | Published pharmacology on each component; combined-protocol literature is limited and clinician-directed. | Largest published trial program of the three for the specific HIV-associated lipodystrophy indication. |
| Typical clinician use case | Considered when a clinician wants the shortest-acting GHRH-only stimulus for an exploratory protocol. | Considered when a clinician wants paired GHRH-plus-secretagogue activity in a single compounded protocol. | Considered when the clinical picture aligns with the FDA-approved indication or with the most clinically characterized GHRH analog of the three. |
| Clinician monitoring | Baseline labs, IGF-1 trend, tolerability follow-up. | Baseline labs, IGF-1 trend, tolerability follow-up. | Baseline labs, IGF-1 trend, glycemic monitoring per clinician judgment. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
Sermorelin is the shortest-acting of the three and is the historical reference point clinicians often start from when discussing the GH axis.
CJC-1295/ipamorelin combines two complementary mechanisms and is one option clinicians consider for paired stimulation.
Tesamorelin has an FDA-approved finished product for a specific indication and is the most clinically characterized of the three; clinician judgment determines fit.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Are sermorelin, CJC-1295/ipamorelin, and tesamorelin the same thing?
No. They all act on the growth-hormone axis but through different molecules and durations of action. Sermorelin and tesamorelin are GHRH analogs; CJC-1295/ipamorelin pairs a GHRH analog with a separate GH secretagogue.
Is any of them FDA-approved?
Tesamorelin has an FDA-approved finished product for a specific HIV-related indication. Sermorelin's prior approved finished product was discontinued. CJC-1295/ipamorelin is available through compounding, not as an FDA-approved combined finished product.
How are they administered?
All three are given as subcutaneous injections in the protocols clinicians use today. Specific schedules differ and are set by the prescribing clinician.
Why combine CJC-1295 with ipamorelin?
The two molecules act on different receptors. CJC-1295 extends GHRH-receptor signaling; ipamorelin selectively triggers GH release through the ghrelin/GHS-R pathway. Pairing them is one approach clinicians use to engage both mechanisms.
What labs are typically reviewed?
Clinicians commonly review baseline labs, IGF-1 trend, and glycemic markers depending on the molecule. Specific monitoring is decided by the prescribing clinician.
Where can these be obtained?
Compounded versions come from 503A or 503B compounding pharmacies on a patient-specific prescription. Tesamorelin's FDA-approved finished product is also a separate route.